image: Figure 4. The influence of 2-BP treatment on the levels of senescence markers. The levels of p-p53 (A), HMGB1 (B), and lamin B1 (C) in cell extracts from VSMCs treated for 24 h with 2-BP before doxorubicin (DOX) treatment (pretreatment) or treated with 2-BP alone for the indicated times were analyzed via Western blotting. Representative Western blots (the cutting line of the blot is shown in red) (D). The results are presented as the means ± SEMs from N=3 biological replicates. Statistical analysis was performed using one-way ANOVA; *p< 0.05, **p<0.01, ***p<0.001.
Credit: © 2024 Krzystyniak et al.
“For the first time, the present study revealed a critical role for protein palmitoylation in the development of a DNA damage-induced senescence phenotype.”
BUFFALO, NY- September 10, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 16 on August 23, 2024, entitled, “2-Bromopalmitate treatment attenuates senescence phenotype in human adult cells - possible role of palmitoylation.”
As noted in the Abstract of the paper, cells may undergo senescence in response to DNA damage, which is associated with cell cycle arrest, altered gene expression and altered cell morphology. Protein palmitoylation is one of the mechanisms by which the DNA damage response is regulated.
Researchers Adam Krzystyniak, Agata Gluchowska, Agata Pytyś, Magdalena Dudkowska, Tomasz Wójtowicz, Alicja Targonska, Dorota Janiszewska, Ewa Sikora, and Grazyna Mosieniak from the Nencki Institute of Experimental Biology in Warsaw, Poland, hypothesized that protein palmitoylation played a role in regulation of the senescent phenotype. They showed that treatment of senescent human vascular smooth muscle cells (VSMCs) with 2-bromopalmitate (2-BP) - an inhibitor of protein acyltransferases - is associated with changes in different aspects of the senescent phenotype, including the resumption of cell proliferation, a decrease in DNA damage markers and the downregulation of senescence-associated β-galactosidase activity.
“Our data suggest that cell senescence may be regulated by palmitoylation, which provides a new perspective on the role of this posttranslational modification in age-related diseases.”
Continue reading: DOI:https://doi.org/10.18632/aging.206080
Corresponding authors: Grazyna Mosieniak - g.mosieniak@nencki.edu.pl, and Adam Krzystyniak - a.krzystyniak@nencki.edu.pl
Video short: https://www.youtube.com/watch?v=_y-Qw8ur8r8
Keywords: aging, cell senescence, vascular smooth muscle cell, palmitoylation, 2-BP, DNA damage
Click here to sign up for free Altmetric alerts about this article.
About Aging-US
The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population.
The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.)
Please visit our website at https://www.Aging-US.com and connect with us:
Facebook - https://www.facebook.com/AgingUS/
X - https://twitter.com/AgingJrnl
Instagram - https://www.instagram.com/agingjrnl/
YouTube - https://www.youtube.com/@AgingJournal
LinkedIn - https://www.linkedin.com/company/aging/
Pinterest - https://www.pinterest.com/AgingUS/
Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc
Click here to subscribe to Aging publication updates.
For media inquiries, please contact media@impactjournals.com.
Aging (Aging-US) Journal Office
6666 E. Quaker St., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957, option 1
Journal
Aging-US
Method of Research
News article
Subject of Research
Cells
Article Title
2-Bromopalmitate treatment attenuates senescence phenotype in human adult cells - possible role of palmitoylation
Article Publication Date
23-Aug-2024
COI Statement
The authors declare that they have no conflicts of interest.